ArticleJournal of gastrointestinal oncology2021

Efficacy of modified bevacizumab-XELOX therapy in Japanese patients with stage IV recurrent or non-resectable colorectal cancer.

Daiki Yokoyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.